Testing a New Ayurvedic Medicine CKD 777 Added to Standard Treatment for Chronic Kidney Disease

Evaluating The Efficacy And Safety Of CKD777 Compared To Standard Care In Chronic Kidney Disease Stages 2 to 4 A Randomized Open Label Non Inferiority Clinical Trial at Yenepoya Medical College Hospital - CKD 777

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/111297

Enrollment

Registered

2026-05-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N182- Chronic kidney disease, stage 2 (mild) Health Condition 2: N183- Chronic kidney disease, stage 3 (moderate) Health Condition 3: N184- Chronic kidney disease, stage 4 (severe)

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Having eGFR greater than or equal to 15 and less than or equal to 60 mL /min /1.73m2 (CKD- EPI Formula)

Exclusion criteria

Exclusion criteria: Q 60. 0- Q 60.6 Renal agenesis and other reduction defects of kidney Q 61.0- Q 61.3 Autosomal dominant or autosomal recessive polycystic kidney disease, Q 62 Congenital obstructive defects of renal pelvis and congenital malformations of ureter Q 63 Other congenital malformations of kidney Q 64 Other congenital malformations of Urinary System E 85 Amyloidosis P-96.0 Congenital Renal failure N 07 Hereditary nephropathy, not elsewhere classified N 17 Acute Renal failure N 18.1 Chronic kidney disease, stage 1 N 29 Other disorders of the kidney & ureter in diseases classified elsewhere E 10 Type 1 diabetes mellitus; Z 33 Pregnant; New York Heart Association (NYHA) class IV Congestive Heart Failure at the time of enrolment; MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment. Receiving cytotoxic therapy, immunosuppressive therapy or other immunotherapy for primary or secondary renal disease within 6 months prior to enrolment; History of organ transplantation prior to enrolment Previous intolerance of an SGLT2 inhibitor.

Design outcomes

Primary

Measure	Time frame
Improvement in eGFR from baseline and reduction in the serum creatinine.Timepoint: Baseline, 12th week and 20th week	—

Secondary

Measure	Time frame
UACR reduction. Serum urea, BUN, electrolytes. Quality of Life scores. Adverse events monitoring.Timepoint: Improvement in eGFR from baseline and reduction in serum creatinine.	—

Countries

India

Contacts

Public ContactDr Reshma Shettigar

Yenepoya Deemed to be University

drreshmas@yenepoya.edu.in7404863848

Outcome results